Knock offs or the real deal? Long known to be safe, effective and approved by the Food and Drug Administration (FDA), generics now make up 80 percent of all prescriptions filled.
On May 24, 2023, PharmAvail successfully submitted 2022 Reference Year data in accordance with the Consolidated Appropriations Act, 2021 (CAA). Section 204 of the CAA requires insurance companies and health plans to submit pharmacy benefit and drug cost data annually.
For our client’s convenience, our team submitted all data free of charge ahead of the June 1 deadline.
The following information was submitted for PharmAvail clients required to submit:
P2: Group Health Plan List
D3: Top 50 Most Frequent Brand Drugs
D4: Top 50 Most Costly Drugs
D5: Top 50 Drugs by Spending Increase
D6: Total Drug Spending (Under Pharmacy Benefit)
D7: Rx Rebates by Therapeutic Class
D8: Rx Rebates for the Top 25 Drugs
We are pleased to provide this service at no charge to our clients. At PharmAvail, we work closely with our clients to ensure their unique needs are met. Known for our high-touch service, actionable analytics, and forward-thinking management strategies, we take a collaborative approach to controlling costs without compromising care.
If you have any questions, please contact us directly at firstname.lastname@example.org.